Journal of Comparative Effectiveness Research is a leading academic journal dedicated to the evaluation of healthcare interventions and practices, published by Becaris Publishing. Since transitioning to a fully Open Access model in 2023, the journal has expanded its accessibility to a global audience of researchers, healthcare professionals, and policy makers. With a focus on comparative effectiveness in health policy, it has achieved a notable ranking of #132 out of 310 in the Scopus category for Medicine and Health Policy, placing it in the 57th percentile for scholarly impact. Operating from the United Kingdom, the journal encompasses research from 2012 to 2024 and firmly establishes itself in the academic landscape as a Q2 journal in the Health Policy category as of 2023. By disseminating high-quality, evidence-based research, the Journal of Comparative Effectiveness Research plays a vital role in informing clinical practice and health policy decision-making, making it an essential resource for those dedicated to improving health outcomes.

Pilot and Feasibility Studies, published by BMC, stands at the forefront of innovative research in the realm of pilot studies and feasibility assessments, serving as a vital resource for researchers in medicine and healthcare. As an Open Access journal since 2015, it provides unrestricted access to its content, promoting the dissemination of significant findings and fostering collaboration among the global research community. Based in the United Kingdom, this journal has solidly established its reputation, ranking in the Q2 quartile for medicine (miscellaneous) in 2023 with a Scopus rank of #183 out of 398, placing it within the 54th percentile. The journal's scope encompasses a wide range of methodologies and applications, encouraging the translation of pilot studies into viable healthcare practices. With a commitment to quality and accessibility, Pilot and Feasibility Studies plays an essential role in enhancing the rigor and impact of preliminary research, ultimately contributing to the advancement of medical science.

JOURNAL OF TELEMEDICINE AND TELECARE, published by SAGE PUBLICATIONS LTD, stands at the forefront of the rapidly evolving fields of health informatics and telemedicine. With its ISSN 1357-633X and E-ISSN 1758-1109, this prestigious journal has been a vital platform for innovation and research since its inception in 1995, covering a wide array of topics from remote patient monitoring to the integration of artificial intelligence in healthcare delivery. Recognized for its rigorous academic standards, the journal boasts an impressive impact factor, positioning it in the Q1 quartile for Health Informatics and securing a remarkable rank of #9 out of 138 in Scopus, placing it in the 93rd percentile among its peers. By disseminating high-quality research, the JOURNAL OF TELEMEDICINE AND TELECARE contributes significantly to the advancement of knowledge, shaping best practices in telehealth and enhancing patient care worldwide. As a non-open access journal, it appeals to a broad audience of researchers, healthcare professionals, and students, facilitating critical discourse on the future of healthcare technology. Stay at the forefront of this essential domain by engaging with the latest findings and projects featured in this influential publication.

Drugs-Real World Outcomes, published by SPRINGERNATURE, is an influential open access journal dedicated to the dissemination of research concerning the real-world impact of pharmacological therapies. Since its inception in 2014, this journal has established a significant presence in the field of Pharmacology, evidenced by its classification in the Q2 quartile for 2023 and a Scopus rank of #141 out of 272 in the medical pharmacology category, placing it in the 48th percentile. The journal’s scope encompasses a diverse range of studies aimed at bridging the gap between clinical research and practical outcomes, making it an essential resource for researchers, healthcare professionals, and students alike. Located in Switzerland, Drugs-Real World Outcomes allows researchers unfettered access to vital data, enhancing knowledge translation and improving health care practices. As it continues to evolve, the journal remains committed to fostering high-quality research that informs and advances the field of pharmacological therapies.

Journal of Health Economics and Outcomes Research, published by COLUMBIA DATA ANALYTICS, LLC, serves as a vital resource in the field of health policy and public health, providing researchers, professionals, and students with open access to pioneering studies since its inception in 2013. With its ISSN and E-ISSN both listed as 2327-2236, this journal aims to disseminate high-quality research that evaluates healthcare efficiency and outcomes. Situated in the United States, at 145 Hudson St., Suite 205, New York, NJ 10013, it has made significant strides in its category quartiles within the 2023 rankings, achieving Q2 status in both Health Policy and Public Health, Environmental and Occupational Health. Furthermore, it maintains respectable Scopus rankings, with a percentile of 51st in health policy and 49th in public health. By bridging gaps in health economics and policy discourse, the journal stands as an indispensable platform for advancing knowledge and fostering innovation in health services research.

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

Health Economics Review is a premier, peer-reviewed journal dedicated to advancing knowledge and research in the dynamic field of health economics and policy. Published by BMC, this Open Access journal has been a vital resource since 2011, providing a platform for scholars and practitioners to share their findings and insights on pressing health policy issues. With an impressive Q2 ranking in the Health Policy category and a Scopus rank of 113 out of 310, it reflects a solid standing within the academic community, capturing a 63rd percentile ranking that underscores its contribution to the field. The journal covers an extensive range of topics including health systems, economic evaluations, and policy analysis, making it essential reading for researchers, health professionals, and policymakers. Located in Germany, with an operational address at CAMPUS, 4 Crinan St, London, the journal is committed to fostering innovation and collaboration in health economics, thereby shaping a healthier future for all.

Cost Effectiveness and Resource Allocation is a premier open-access journal published by BMC, dedicated to advancing the field of health policy and economics. Since its inception in 2003, the journal has provided a platform for researchers, policymakers, and healthcare professionals to disseminate crucial findings and insights relevant to cost-effectiveness analyses and resource allocation strategies. With an increasing impact factor and ranking within the Q2 category of health policy journals, it ranks #138 out of 310 in Scopus, placing it in the 55th percentile among its peers. The journal aims to facilitate knowledge exchange that can transform health policy and improve healthcare delivery through rigorous research, evaluation, and dialogue. Open access since its establishment, it ensures that critical findings are available to a global audience, thereby enhancing the impact and reach of its published works.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

Global & Regional Health Technology Assessment (ISSN: 2284-2403; E-ISSN: 2283-5733) is an esteemed open-access journal published by ABOUTSCIENCE SRL, dedicated to the dissemination of research in the field of health technology assessment on a global and regional scale. Since its inception in 2014, this journal has focused on the critical evaluation of health technologies, providing invaluable insights into their efficacy, cost-effectiveness, and impact on healthcare systems. With an increasing emphasis on public health and policy implications, the journal encourages interdisciplinary research that bridges gaps between technological innovations and health outcomes. Despite its relatively recent establishment, it has made significant inroads with Scopus rankings reflecting the growing importance of health technology assessment in global health discourse. The journal welcomes contributions from researchers, professionals, and students, inviting them to engage in discussions that shape the future of health technology, with the aim of informing stakeholders and policymakers worldwide.